|Articles|July 6, 2020

China Confirms Case of Bubonic Plague

Health officials in China have confirmed a case of bubonic plague in a herdsman from the Inner Mongolia district, triggering increased prevention measures throughout the region.

Health officials in China have confirmed a case of bubonic plague in a herdsman from the Inner Mongolia district, triggering increased prevention measures throughout the region, according to the Bayannur city health commission.

The man, who was diagnosed Sunday, is under isolation at a local hospital where he is receiving treatment and reported to be in stable condition.

>>> The infectious disease news you want, anytime you want. Sign up for the Contagion newsletter.

The city health commission has issued a Level 3 warning to last until the end of year, urging residents not to hunt, transport, or consume potentially infected animals, including marmots, and to practice good infection prevention measures.

"At present, there is a risk of a human plague epidemic spreading in this city. The public should improve its self-protection awareness and ability, and report abnormal health conditions promptly," the local health authority said, according to China Daily.

The confirmed case follows 2 others reported last week in Mongolia in brothers who had consumed marmot meat, Xinhua news agency reported.

Caused by the Yersinia pestis bacterium, bubonic plague is spread via the bites of infected fleas from small mammals.

"The lymph node then becomes inflamed, tense and painful, and is called a 'bubo,'" according to the World Health Organization. "At advanced stages of infection the inflamed lymph nodes can turn into open sores filled with puss. Human to human transmission of bubonic plague is rare. Bubonic plague can advance and spread to the lungs, which is the more severe type of plague called Pneumonic plague."

Without treatment, plague’s case-fatality ratio ranges from 30% to 100%.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.